据港交所2月25日披露，山东汉方制药股份有限公司(简称：汉方制药)向港交所主板递交上市申请书，中泰国际为其独家保荐人。 公司简介 招股书显示，汉方制药是一家从事中医药产品的生产、销售与研发的综合制药公司。公司专注于皮肤及黏膜疾病治疗领域，善于将 传统中医智慧与现代医药科学相融合。根据弗若斯特沙利文的资料，按2024年销售收入计，复方黄柏液涂剂在中国外用中成药市场 排名第四，占据1.1%的市场份额。在此成熟产品的成功基础上，公司正透过提供化妆品及其他中成药产品拓展产品组合。 汉方制药的旗舰产品复方黄柏液涂剂为目前中国中成药领域中唯一获批的处方涂剂，其为国家二级中药保护品种，根据《中药品种 保护条例》，该认定授予其独家保护，依法禁止任何其他实体生产相同药品。该国家二级保护地位使公司享有复方黄柏液涂剂的独 家市场地位，而无相同药品构成直接竞争。 作为市场领导者，汉方制药认为复方黄柏液涂剂将受惠于稳定增长的市场，巩固公司的竞争地位。在复方黄柏液涂剂的成功奠定的 基础之上，公司通过三大核心战略积极推进多元化产品组合：(i)推进新型中成药产品研发；(ii)将经临床验证的医疗机构制剂或临床 经验方转化为创新型、具备上市条件 ...

智通财经APP获悉，据港交所2月25日披露，山东汉方制药股份有限公司(简称：汉方制药)向港交所主板递交上市申请书，中泰国际 为其独家保荐人。 公司简介 招股书显示，汉方制药是一家从事中医药产品的生产、销售与研发的综合制药公司。公司专注于皮肤及黏膜疾病治疗领域，善于将 传统中医智慧与现代医药科学相融合。根据弗若斯特沙利文的资料，按2024年销售收入计，复方黄柏液涂剂在中国外用中成药市场 排名第四，占据1.1%的市场份额。在此成熟产品的成功基础上，公司正透过提供化妆品及其他中成药产品拓展产品组合。 汉方制药的旗舰产品复方黄柏液涂剂为目前中国中成药领域中唯一获批的处方涂剂，其为国家二级中药保护品种，根据《中药品种 保护条例》，该认定授予其独家保护，依法禁止任何其他实体生产相同药品。该国家二级保护地位使公司享有复方黄柏液涂剂的独 家市场地位，而无相同药品构成直接竞争。 作为市场领导者，汉方制药认为复方黄柏液涂剂将受惠于稳定增长的市场，巩固公司的竞争地位。在复方黄柏液涂剂的成功奠定的 基础之上，公司通过三大核心战略积极推进多元化产品组合：(i)推进新型中成药产品研发；(ii)将经临床验证的医疗机构制剂或临床 经验方转化 ...

Core Viewpoint - The company Pianzaihuang has a strong brand presence and cultural heritage, which contributes to its unique brand advantages and recognition in the market [2] Brand Recognition - Pianzaihuang has achieved significant accolades, including ranking first in the "2024 Hurun Medical Health Brand Value List" and maintaining the top position in the "Hurun China's Most Culturally Rich Brands List" for three consecutive years from 2022 to 2024 [2] - The brand value of Pianzaihuang is reported at 43.739 billion yuan, earning it the top spot in the "2024 Chinese Time-Honored Brand List" [2] Market Position - The company has established a strong reputation both domestically and internationally, being recognized as a leading exporter of traditional Chinese medicine products [2] - Pianzaihuang is referred to as a "Chinese symbol" along the Maritime Silk Road, indicating its significant role in promoting Chinese culture abroad [2] Consumer Confidence - The company's positive brand image has garnered widespread acclaim and recognition from various sectors, fostering consumer confidence in its products [2]

Core Viewpoint - Recently, the company Tian Shi Li announced the termination of its cooperation agreement with the US company Arbor, halting the joint plan for the compound Danshen dripping pill (T89) in the US market. Although the company stated it would recover related rights and receive $7.5 million, and that this would not have a significant impact on its production and operations, the event reflects the multifaceted risks and challenges faced by Tian Shi Li in the internationalization of traditional Chinese medicine, research and development progress, and corporate operations [1][4]. Group 1: Internationalization Strategy Challenges - The compound Danshen dripping pill has been under FDA clinical application in the US since 1998, making it a landmark project for the internationalization of traditional Chinese medicine. However, the termination of the partnership with Arbor signifies a setback in the strategy of leveraging local partners for market entry [5][6]. - Despite the company emphasizing its accumulated international clinical experience and that the application process is not entirely dependent on Arbor, the exit of the partner undoubtedly increases the uncertainty of its independent advancement. Currently, the two indications for the drug—chronic stable angina and acute altitude sickness—are still in phase III clinical trials, with no clear timeline for final approval [6]. Group 2: Research and Development Progress and Regulatory Risks - The approval process for the compound Danshen dripping pill in the US has been fraught with difficulties. In 2017, the FDA required the company to complete a second confirmatory clinical trial in addition to an already completed phase III trial, with both trials needing to achieve statistical significance (p<0.05). The first trial took about four years, and the second trial, which started in 2018, has exceeded four years without results [2][6]. - This prolonged and high-investment clinical process not only brings financial pressure but also reflects the stringent challenges faced by traditional Chinese medicine formulations under Western regulatory systems. If the results of the second clinical trial do not meet the standards, years of effort may be wasted. The company's "lone battle" in the internationalization of traditional Chinese medicine—where only a few traditional Chinese medicine products have attempted to navigate the FDA—also makes it difficult to learn from peers, leading to high trial-and-error costs [2][6]. Group 3: Operational Difficulties and Transformation Challenges - The journey of the compound Danshen dripping pill abroad mirrors the development trajectory of Tian Shi Li in recent years. The company's revenue approached 19 billion yuan between 2016 and 2019, but has since been under pressure due to the sale of its marketing subsidiary and the impact of medical insurance cost control and centralized procurement policies. In 2025, the company's revenue was 8.236 billion yuan, a year-on-year decline of 3.08%, while the net profit excluding non-recurring items was 786 million yuan, down 24.06% year-on-year, indicating a continued lack of growth momentum [2][7]. - Additionally, the company officially integrated into the China Resources Sanjiu system in 2025, which may provide resource support but also means that its original development strategy will face adjustments. In the context of weak growth in its main business and slow internationalization progress, how Tian Shi Li repositions its core competitive path will be a key question for its future development [7]. Conclusion - The "American dream" of the compound Danshen dripping pill remains unfulfilled, while Tian Shi Li has entered a new development cycle. From self-research challenges to setbacks in cooperation, and from peak performance to integration and transformation, the case of this leading traditional Chinese medicine enterprise illustrates that the internationalization of traditional Chinese medicine involves not only technical compliance and clinical data but also a multifaceted test of corporate strategic determination, financial endurance, and market adaptability. The company still needs to find a feasible path to bridge traditional Chinese medicine and modern pharmaceutical systems [3][8].

Core Viewpoint - The National Healthcare Security Administration (NHSA) is set to adjust the National Medical Insurance Drug List in 2026, focusing on optimizing the review process and ensuring alignment with the current healthcare fund capabilities and drug supply conditions [1][4]. Group 1: Drug List Adjustment - The adjustment will prioritize Traditional Chinese Medicine (TCM) that has unclear adverse reactions, which will be targeted for removal from the list [1][3]. - The NHSA emphasizes a transparent and scientific review process, enhancing public communication regarding the adjustment logic and evaluation criteria [1][2]. Group 2: Reference Drug Communication - The NHSA has introduced a "Reference Drug Communication Method" to optimize the evaluation rules, allowing innovative drugs to apply for reference drug status earlier in the process [2][4]. - The selection of reference drugs will now occur before the traditional evaluation phase, enabling companies to prepare more comprehensive economic and clinical data [2][3]. Group 3: Focus on Traditional Chinese Medicine - TCM drugs with "unclear" labels regarding contraindications and adverse reactions will face stricter scrutiny, with new applications likely to be denied if such issues are present [3][5]. - A significant increase in drug applications is expected, with a 30% to 40% rise in 2025 compared to 2024, driven by a large existing drug inventory and accelerated approvals of innovative drugs [3][6]. Group 4: Regulatory Measures and Market Dynamics - The NHSA's ongoing efforts to regulate TCM include a focus on improving the quality of drug labels and ensuring that outdated or ineffective drugs are phased out [6][8]. - High-priced TCM products lacking unique therapeutic effects will be increasingly excluded from the market, as the NHSA has initiated multiple price governance actions [9].

Core Viewpoint - The National Healthcare Security Administration (NHSA) is set to adjust the National Medical Insurance Drug List in 2026, focusing on optimizing the review process and ensuring alignment with the current healthcare fund's payment capacity and drug supply situation [1][7]. Group 1: Drug List Adjustment Principles - The adjustment will adhere to the principles of steady progress and continuous optimization, emphasizing transparency and scientific evaluation in the review process [1][5]. - Traditional Chinese medicine (TCM) products with unclear adverse reactions will be prioritized for removal from the list [1][7]. Group 2: Reference Drug Communication Method - The NHSA has introduced a trial method for reference drug communication, which will allow for the selection of reference drugs to assess the value of new drug applications [3][5]. - This method aims to enhance the preparation of economic and clinical data by allowing early application for reference drug determination [5]. Group 3: Focus on Traditional Chinese Medicine - TCM products will be a key focus in the upcoming adjustments, particularly those with "unclear" labels in their instructions regarding contraindications and adverse reactions [5][7]. - From July 1, 2026, TCM products with unclear safety information will not be approved for re-registration, impacting those already on the list [5][11]. Group 4: Increase in Drug Applications - The number of drug applications for the National Medical Insurance Drug List has surged, with a projected increase of 30% to 40% in 2025 compared to 2024, and further growth expected in 2026 [6]. - The rapid approval of innovative drugs, with 76 new first-class innovative drugs approved in 2025, contributes to this increase [6]. Group 5: Regulatory Trends and Challenges - The tightening of regulations around TCM products indicates a rising barrier to entry, with a focus on eliminating products that lack clinical efficacy and have unclear safety profiles [11][12]. - The NHSA has been actively conducting price governance actions against TCM products that are overpriced without unique therapeutic effects, leading to their potential exclusion from reimbursement [12].

经济观察网仁和药业（000650）近期发生董事会秘书变更，并回应了潜在重组事项，同时公司跨界布局 智能硬件，调整募投项目，业绩持续承压，需关注政策合规动态。 高管变动 2026年2月9日，公司公告董事会秘书陈国锋因个人原因辞职，由姜锋接任该职务。此次人事变动已完成 工作交接，公司称不会影响正常运营。 近期事件 项目进展 2025年12月，公司公告调整女性生理健康用品生产线项目，终止数字化保健产品线，并将剩余募集资金 用于补充流动资金。这一举措反映了公司战略收缩动向。 业绩经营情况 2025年前三季度，公司营业收入同比下降10.07%，归母净利润同比下降8.79%。投资者可关注后续年度 财报是否出现改善。 政策监管 2026年1月29日，公司表示《中药注册管理专门规定》的新要求暂未对中成药经营产生重大影响，但需 持续关注法规落地对业务的影响。 在2026年2月2日的投资者互动中，公司回应称，若有重大重组计划，将严格按照法规进行公告。这提示 投资者需关注后续可能的相关披露。 业务进展情况 公司于2025年12月宣布进军AI智能穿戴领域，推出ULOOK AI眼镜，并正推动其上市销售。这一战略转 型可能带来新的业务增 ...

近年来，东阿阿胶（000423）把培育"第二增长曲线"放在公司发展的紧要位置。2月11日，东阿阿胶宣 布，拟以14.85亿元投资建设健康消费品产业园项目，将匹配年轻消费群体对滋补健康产品的消费诉 求。 具体来看，2月11日，东阿阿胶发布公告称，公司拟以14.85亿元（其中固定资产投资14.21亿元，铺底流 动资金0.64亿元）的自有资金投资建设健康消费品产业园项目，用于药食同源食品、保健品、功能性食 品等健康消费品的生产与配套仓储物流、质检中心、新品孵化中心、电商分拣及药品成品仓储等。 据了解，东阿阿胶主要从事阿胶和阿胶系列及其他中成药等产品的研发、生产和销售。 目前，东阿阿胶阿胶及系列产品为公司贡献较大营收。2025年上半年，东阿阿胶来自阿胶及系列产品的 营业收入为28.45亿元，占比超九成。 值得一提的是，近年来，东阿阿胶逐渐面临原材料供应紧张的情况。近年来，国内驴存栏量下降已成为 行业共识，阿胶的主要原料驴皮也随之紧俏。 据了解，近年来，全国各地驴肉价格呈现快速上涨态势，从活驴收购到终端零售均承受一定压力。截至 2026年初，驴肉价格仍处于高位。 东阿阿胶曾在2025年半年报中直言，随着农业运输机械化的 ...

Core Viewpoint - Dong'e Ejiao is prioritizing the cultivation of a "second growth curve" by investing in a health consumer goods industrial park to meet the consumption demands of younger consumers for health products [1][3]. Investment and Project Details - The company plans to invest 1.485 billion yuan (including 1.421 billion yuan for fixed assets and 64 million yuan for working capital) in the industrial park project, which will focus on the production and logistics of health consumer goods, including food and health supplements [1][3]. - The project aims to align with the rapid development of the health industry and the emerging trend of "health management for the young," providing a core driving force for future performance growth [3]. Business Strategy and Market Position - Dong'e Ejiao is expanding its health consumer goods business alongside its pharmaceutical operations, aiming to create a dual-driven growth model [5]. - The construction of the new facility is seen as a proactive attempt to address the challenges posed by tight raw material supplies, particularly the scarcity of donkey hides, which are essential for their main product, Ejiao [5]. Raw Material Supply Challenges - The company is facing a tightening supply of raw materials, particularly due to a decline in the domestic donkey population, which has led to rising prices for donkey meat and hides [4]. - The chairman of Aoyou International emphasized the need for Dong'e Ejiao to transition from passive reliance on raw materials to actively building a complete industry chain ecosystem to ensure sustainable growth [4].

近年来，东阿阿胶（000423）把培育"第二增长曲线"放在公司发展的紧要位置。2月11日，东阿阿胶宣布，拟以14.85亿元投资建设健康消费品产业园项目， 将匹配年轻消费群体对滋补健康产品的消费诉求。 具体来看，2月11日，东阿阿胶发布公告称，公司拟以14.85亿元（其中固定资产投资14.21亿元，铺底流动资金0.64亿元）的自有资金投资建设健康消费品产 业园项目，用于药食同源食品、保健品、功能性食品等健康消费品的生产与配套仓储物流、质检中心、新品孵化中心、电商分拣及药品成品仓储等。 据了解，东阿阿胶主要从事阿胶和阿胶系列及其他中成药等产品的研发、生产和销售。 目前，东阿阿胶阿胶及系列产品为公司贡献较大营收。2025年上半年，东阿阿胶来自阿胶及系列产品的营业收入为28.45亿元，占比超九成。 值得一提的是，近年来，东阿阿胶逐渐面临原材料供应紧张的情况。近年来，国内驴存栏量下降已成为行业共识，阿胶的主要原料驴皮也随之紧俏。 据了解，近年来，全国各地驴肉价格呈现快速上涨态势，从活驴收购到终端零售均承受一定压力。截至2026年初，驴肉价格仍处于高位。 东阿阿胶曾在2025年半年报中直言，随着农业运输机械化的提高和城镇 ...